logo
#

Latest news with #ACG

Aviation Capital Group Announces Delivery of One Boeing 737-8 MAX to Virgin Australia
Aviation Capital Group Announces Delivery of One Boeing 737-8 MAX to Virgin Australia

Business Wire

time2 hours ago

  • Business
  • Business Wire

Aviation Capital Group Announces Delivery of One Boeing 737-8 MAX to Virgin Australia

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Aviation Capital Group LLC (ACG), a premier global full-service aircraft asset manager, announced the delivery of one Boeing 737-8 MAX aircraft to Virgin Australia. This is the first of three aircraft to deliver to the carrier from ACG's order book with Boeing. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable federal securities laws. Any such statements, other than statements of historical fact, are based upon our current expectations and assumptions concerning future events, which are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Accordingly, such statements are not guarantees or assurances of any aspect of future performance. Except as required by applicable law, we do not undertake any obligation to, and will not, update any forward-looking statements, whether as a result of new information, future events or otherwise. About Aviation Capital Group Aviation Capital Group is one of the world's premier full-service aircraft asset managers with approximately 500 owned, managed and committed aircraft as of March 31, 2025, leased to roughly 80 airlines in approximately 45 countries. It specializes in commercial aircraft leasing and provides certain aircraft asset management services and aircraft financing solutions for third parties. It was founded in 1989 and is a wholly owned subsidiary of Tokyo Century Corporation. Follow ACG on LinkedIn, and for more information, visit

Aviation Capital Group Announces Delivery of One A321neo to Sunclass Airlines
Aviation Capital Group Announces Delivery of One A321neo to Sunclass Airlines

Business Wire

timea day ago

  • Business
  • Business Wire

Aviation Capital Group Announces Delivery of One A321neo to Sunclass Airlines

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Aviation Capital Group LLC (ACG), a premier global full-service aircraft asset manager, announced the delivery of one A321neo aircraft to Sunclass Airlines. Featuring CFM International LEAP-1A engines, the aircraft was delivered to the carrier from ACG's order book with Airbus. 'We are delighted to strengthen further our relationship with Sunclass Airlines with the delivery of this fuel-efficient A321neo aircraft,' said Marine Benoit, Vice President, Marketing at ACG. 'This new aircraft will support Sunclass Airlines' fleet modernization program.' 'We're very pleased to welcome this new Airbus A321neo to the Sunclass Airlines fleet,' said Valdemar Warburg, Chief Executive Officer of Sunclass Airlines. 'Its exceptional fuel efficiency and range align perfectly with our sustainability goals and will help us reduce emissions across our operations. The A321neo also allows us to explore new destinations and further enhance the travel experience for our guests. We're grateful for our strong partnership with ACG, whose professionalism has been instrumental in supporting our fleet growth.' About Aviation Capital Group Aviation Capital Group is one of the world's premier full-service aircraft asset managers with approximately 500 owned, managed and committed aircraft as of March 31, 2025, leased to roughly 80 airlines in approximately 45 countries. It specializes in commercial aircraft leasing and provides certain aircraft asset management services and aircraft financing solutions for third parties. It was founded in 1989 and is a wholly owned subsidiary of Tokyo Century Corporation. Follow ACG on LinkedIn, and for more information, visit

Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock
Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock

Globe and Mail

time16-07-2025

  • Business
  • Globe and Mail

Hyperscale Data Declares Monthly Cash Dividend of $0.2708333 per Share of 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock

LAS VEGAS, July 16, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (' Hyperscale Data ' or the ' Company '), today announced that its Board of Directors (the ' Board ') has declared a monthly cash dividend of $0.2708333 per share of the Company's outstanding 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock. The record date for this dividend is July 31, 2025, and the payment date is Monday, August 11, 2025. Link to NYSE quote for the Company's 13.00% Series D Cumulative Redeemable Perpetual Preferred Stock: The Company also announced today that the Board has declared a monthly cash dividend of $0.20833 per share of the Company's outstanding 10.00% Series E Cumulative Redeemable Perpetual Preferred Stock. The record date for this dividend is July 31, 2025, and the payment date is Monday, August 11, 2025. For more information on Hyperscale Data and its subsidiaries, Hyperscale Data recommends that stockholders, investors, and any other interested parties read Hyperscale Data's public filings and press releases available under the Investor Relations section at or available at About Hyperscale Data, Inc. Through its wholly owned subsidiary Sentinum, Inc., Hyperscale Data owns and operates a data center at which it mines digital assets and offers colocation and hosting services for the emerging artificial intelligence (' AI ') ecosystems and other industries. Hyperscale Data's other wholly owned subsidiary, Ault Capital Group, Inc. (' ACG '), is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact. Hyperscale Data currently expects to divest itself of ACG (the ' Divestiture ') on or about December 31, 2025, though there can be no assurance that the Divestiture will be completed during 2025. Upon the occurrence of the Divestiture, the Company would solely be an owner and operator of data centers to support high-performance computing services, though it may at that time continue to operate in the digital asset space as described in the Company's filings with the SEC. Until the Divestiture occurs, the Company will continue to provide, through ACG and its wholly and majority-owned subsidiaries and strategic investments, mission-critical products that support a diverse range of industries, including an AI software platform, social gaming platform, equipment rental services, defense/aerospace, industrial, automotive, medical/biopharma and hotel operations. In addition, ACG is actively engaged in private credit and structured finance through a licensed lending subsidiary. Hyperscale Data's headquarters are located at 11411 Southern Highlands Parkway, Suite 190, Las Vegas, NV 89141. On December 23, 2024, the Company issued one million (1,000,000) shares of a newly designated Series F Exchangeable Preferred Stock (the ' Series F Preferred Stock ') to all common stockholders and holders of the Series C Convertible Preferred Stock on an as-converted basis. The Divestiture will occur through the voluntary exchange of the Series F Preferred Stock for shares of Class A Common Stock and Class B Common Stock of ACG (collectively, the ' ACG Shares '). The Company reminds its stockholders that only those holders of the Series F Preferred Stock who agree to surrender such shares, and do not properly withdraw such surrender, in the exchange offer through which the Divestiture will occur, will be entitled to receive the ACG Shares and consequently be stockholders of ACG upon the occurrence of the Divestiture. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'believes,' 'plans,' 'anticipates,' 'projects,' 'estimates,' 'expects,' 'intends,' 'strategy,' 'future,' 'opportunity,' 'may,' 'will,' 'should,' 'could,' 'potential,' or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company's business and financial results are included in the Company's filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's Forms 10-K, 10-Q and 8- K. All filings are available at and on the Company's website at

ACG Refreshes Preventive Care in IBD Guidance
ACG Refreshes Preventive Care in IBD Guidance

Medscape

time14-07-2025

  • Health
  • Medscape

ACG Refreshes Preventive Care in IBD Guidance

The American College of Gastroenterology has issued an updated clinical practice guideline on preventive care for patients with inflammatory bowel disease (IBD) that covers vaccinations, cancer surveillance, bone health monitoring, lifestyle counseling, and other important 'health maintenance' issues. 'Patients with IBD often consider their gastroenterologist to be the primary provider of care. Because more than 70% of patients with IBD will at some time be on medications that will affect the immune system, it is essential that the gastroenterology team promote vaccinations and other health maintenance activities,' said the writing group, led by Francis Farraye, MD, director, Inflammatory Bowel Disease Center, Mayo Clinic, Jacksonville, Florida. The panel noted that referral to dermatology, endocrinology, gynecology, primary care, and psychiatry 'may be necessary on a case-by-case basis. Coordination between the gastroenterology team and other providers is crucial for improving the quality of care that we provide to our patients living with IBD.' The 27-page updated guideline on preventive care in IBD was published earlier this month in The American Journal of Gastroenterology , along with a one-page visual highlights summary. The update provides 12 recommendation statements and 11 key concepts. It replaces the 2017 ACG guideline on preventive care in IBD. Prioritize Vaccinations 'Patients with IBD are at increased risk for infections as a consequence of their disease, and this risk may be amplified by certain immune-modifying therapies,' the writing group noted. They strongly recommend that all adults with IBD aged 50 years and older with no prior pneumococcal vaccination receive the pneumococcal conjugate vaccine (PCV) 20 or PCV21. There is a conditional recommendation that adults aged 19-49 years on immune-modifying therapy and with no prior pneumococcal vaccination also receive the PCV20 or PCV21 vaccine. Patients with IBD who previously received a pneumococcal vaccine should follow revaccination advice from the CDC. Vaccination against herpes zoster with the two-dose inactive recombinant herpes zoster vaccine is advised for patients with IBD aged 50 years or more and for younger patients about to start or already on immune-modifying therapy (both conditional recommendations). Other conditional recommendations include vaccination against SARS-CoV-2 in accordance with national guidelines and live rotavirus vaccine for children with in-utero exposure to biologics. In addition, all adults with IBD should receive annual influenza vaccines; those receiving immune-modifying therapies and their household contacts should receive the nonlive trivalent inactivated influenza vaccine but not the live inhaled influenza vaccine. Respiratory syncytial virus (RSV) vaccine is advised for all patients aged 75 and older and for those aged 50-74 years with certain chronic medical conditions or other risk factors for severe RSV disease. Household members of patients receiving immune-modifying therapies can receive live vaccines with certain precautions. Vaccinations against tetanus, diphtheria, and pertussis (Tdap), hepatitis A virus, human papillomavirus (HPV), and meningococcus should be administered according to CDC recommendations. Adults with IBD should receive vaccination against hepatitis B if not immune. Skin and Cervical Cancer Surveillance 'In addition to vaccination issues, it is important to identify subgroups of patients with IBD that have an increased risk of developing cervical cancer, nonmelanoma skin cancer (NMSC), and melanoma,' the panel said. In women with IBD on immune-modifying therapies, there is a conditional recommendation for annual cervical cancer screening within a year of sexual activity onset; in women younger than 30 years, screening should continue for 3 consecutive years before increasing to every 3 years. Annual screening for melanoma (independent of biologic therapy) and for NMSC (particularly in adults aged 50+) is also suggested (conditional recommendations). Bone and Mental Health Patients with IBD are at increased risk for bone loss, which can lead to osteopenia and osteoporosis. The guideline suggests screening for osteoporosis with bone mineral density testing at the time of diagnosis and periodically after diagnosis (conditional recommendation). Given data showing worse outcomes among smokers with IBD, smoking cessation counseling is strongly encouraged. The guideline also addresses the mental health of patients with IBD. 'Current evidence suggests that mood disorders, in particular depression and anxiety, are more prevalent in patients with IBD than the background population, the panel noted. Therefore, they recommend that all patients with IBD be screened for depression and anxiety at baseline and annually. Patients who screen positive for anxiety and/or depression should be referred for counseling/therapy.

2 men arrested in Las Piñas for selling fake money online
2 men arrested in Las Piñas for selling fake money online

GMA Network

time04-07-2025

  • GMA Network

2 men arrested in Las Piñas for selling fake money online

Two suspects were arrested in Las Piñas City for selling fake money online, the Anti-Cybercrime Group (ACG) of the Philippine National Police said Friday. In a statement, the ACG said the suspects, identified as 18-year-old 'Usa' and 30-year-old 'Agila,' were arrested in an entrapment operation on Wednesday. This was in response to the report from the Bangko Sentral ng Pilipinas (BSP) regarding the online sale of counterfeit banknotes. The Northern District Anti-Cybercrime Team conducted cyber patrolling and caught a social media post by one of the suspects offering a counterfeit P1,000 bill for only P150. Seized from the suspects were 150 fake P1,000 bills sold for P22,500 during the operation. The suspects are facing charges for illegal possession and use of false treasury or banknotes and other instruments of credit under Article 168 of the Revised Penal Code in relation to Section 6 of the Cybercrime Prevention Act of 2012. 'The sale of counterfeit currency online undermines our financial system and exploits the trust of unsuspecting citizens. Let this serve as a warning to those attempting to use the internet to circulate fake money,' ACG chief Police Brigadier General Bernard Yang said. 'The PNP ACG is actively monitoring these platforms and will act decisively to bring offenders to justice as we remain committed to protecting the public and preserving the integrity of our currency,' he added. —Joviland Rita/ VAL, GMA Integrated News

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store